{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:25:30Z","timestamp":1787063130060,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40261-026-01583-7","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T19:37:05Z","timestamp":1784057825000},"page":"965-984","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["JAK Inhibitors in Inflammatory Skin Diseases: A 15,427-Patient Systematic Review and Meta-analysis of Clinical Trial and Real-World Outcomes"],"prefix":"10.1007","volume":"46","author":[{"given":"Nada Faheem","family":"Zayed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Seetan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6282-8351","authenticated-orcid":false,"given":"Almu\u2019atasim","family":"Khamees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0435-4124","authenticated-orcid":false,"given":"Raghad Yousef","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1927-8507","authenticated-orcid":false,"given":"Saleh A.","family":"Ba-shammakh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"issue":"4","key":"1583_CR1","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","volume":"76","author":"W Damsky","year":"2017","unstructured":"Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736\u201344.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1583_CR2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s13555-019-00329-y","volume":"9","author":"AM Montilla","year":"2019","unstructured":"Montilla AM, Gomez-Garcia F, Gomez-Arias PJ, Gay-Mimbrera J, Hernandez-Parada J, Isla-Tejera B, et al. Scoping review on the use of drugs targeting JAK\/STAT pathway in atopic dermatitis, vitiligo, and alopecia areata. Dermatol Ther (Heidelb). 2019;9(4):655\u201383.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"10246","key":"1583_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255\u201366.","journal-title":"Lancet"},{"issue":"8","key":"1583_CR4","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863\u201373.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1583_CR5","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, Thaci D, Paul C, Pink AE, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101\u201312.","journal-title":"N Engl J Med"},{"issue":"3","key":"1583_CR6","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","volume":"145","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Thaci D, Pangan AL, Hong HC, Papp KA, Reich K, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877\u201384.","journal-title":"J Allergy Clin Immunol"},{"issue":"10290","key":"1583_CR7","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169\u201381.","journal-title":"Lancet"},{"issue":"5","key":"1583_CR8","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.15489","volume":"33","author":"K Phan","year":"2019","unstructured":"Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019;33(5):850\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1583_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1342810","volume":"15","author":"Q He","year":"2024","unstructured":"He Q, Xie X, Chen Q, Li W, Song Z, Wang X, et al. Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses. Front Immunol. 2024;15:1342810.","journal-title":"Front Immunol"},{"issue":"1","key":"1583_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.133","volume":"3","author":"KP Lee","year":"2023","unstructured":"Lee KP, Plante J, Korte JE, Elston DM. Oral Janus kinase inhibitors in the treatment of atopic dermatitis: a systematic review and meta-analysis. Skin Health Dis. 2023;3(1):e133.","journal-title":"Skin Health Dis."},{"issue":"4","key":"1583_CR11","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1159\/000518541","volume":"238","author":"C Li","year":"2022","unstructured":"Li C, Sun X, Zhao K, Meng F, Li L, Mu Z, et al. Efficacy and safety of janus kinase inhibitors for the treatment of atopic dermatitis: a systematic review and meta-analysis. Dermatology (Basel). 2022;238(4):725\u201335.","journal-title":"Dermatology (Basel)"},{"key":"1583_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1195858","volume":"14","author":"MQ Mao","year":"2018","unstructured":"Mao MQ, Ding YX, Jing J, Tang ZW, Miao YJ, Yang XS, et al. The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients. Front Immunol. 2018;14:1195858.","journal-title":"Front Immunol"},{"key":"1583_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11040279","author":"HR Tsai","year":"2021","unstructured":"Tsai HR, Lu JW, Chen LY, Chen TL. Application of janus kinase inhibitors in atopic dermatitis: an updated systematic review and meta-analysis of clinical trials. J Pers Med. 2021. https:\/\/doi.org\/10.3390\/jpm11040279.","journal-title":"J Pers Med"},{"key":"1583_CR14","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2020;372:n160.","journal-title":"BMJ"},{"issue":"10290","key":"1583_CR15","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151\u201368.","journal-title":"Lancet"},{"issue":"2","key":"1583_CR16","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242\u201355.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1583_CR17","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","volume":"148","author":"R Chovatiya","year":"2021","unstructured":"Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021;148(4):927\u201340.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"1583_CR18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/bjd.16014","volume":"178","author":"H Nakagawa","year":"2018","unstructured":"Nakagawa H, Nemoto O, Igarashi A, Nagata T. Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study. Br J Dermatol. 2018;178(2):424\u201332.","journal-title":"Br J Dermatol"},{"issue":"14","key":"1583_CR19","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","volume":"379","author":"K Papp","year":"2018","unstructured":"Papp K, Gordon K, Thaci D, Morita A, Gooderham M, Foley P, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018;379(14):1313\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"1583_CR20","doi-asserted-by":"publisher","first-page":"s119","DOI":"10.25251\/skin.7.supp.119","volume":"7","author":"NJ Korman","year":"2023","unstructured":"Korman NJ, Passeron T, Gordon KB, Okubo Y, Bagel J, Sofen H, et al. Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program. SKIN J Cutan Med. 2023;7(2):s119-s.","journal-title":"SKIN J Cutan Med"},{"issue":"9993","key":"1583_CR21","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","volume":"386","author":"H Bachelez","year":"2015","unstructured":"Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015;386(9993):552\u201361.","journal-title":"Lancet"},{"issue":"6","key":"1583_CR22","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/bjd.14403","volume":"174","author":"KA Papp","year":"2016","unstructured":"Papp KA, Menter MA, Raman M, Disch D, Schlichting DE, Gaich C, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2016;174(6):1266\u201376.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1583_CR23","doi-asserted-by":"publisher","first-page":"590","DOI":"10.25259\/IJDVL_775_2023","volume":"90","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Han Y, Chen J, Huang J, Zhu C, Lin L, et al. Comparative efficacy and safety of JAK\/TYK2 inhibitors and other oral drugs for moderate-to-severe plaque psoriasis: Systematic review and network meta-analysis. Indian J Dermatol Venereol Leprol. 2024;90(5):590\u20138.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"9","key":"1583_CR24","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1007\/s00403-024-03325-1","volume":"316","author":"D Sharma","year":"2024","unstructured":"Sharma D, Gart S, Kitrell B, Lonowski S, Arthur M, Wei EX. Analysis of patient experiences regarding JAK inhibitors for atopic dermatitis, psoriasis, alopecia areata, and vitiligo. Arch Dermatol Res. 2024;316(9):630.","journal-title":"Arch Dermatol Res"},{"issue":"18","key":"1583_CR25","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399.","journal-title":"N Engl J Med"},{"issue":"6","key":"1583_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.20351","volume":"6","author":"M Liu","year":"2023","unstructured":"Liu M, Gao Y, Yuan Y, Yang K, Shen C, Wang J, et al. Janus kinase inhibitors for alopecia areata: a systematic review and meta-analysis. JAMA Netw Open. 2023;6(6):e2320351.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"1583_CR27","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/jdv.19797","volume":"38","author":"H Husein-ElAhmed","year":"2024","unstructured":"Husein-ElAhmed H, Husein-ElAhmed S. Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: a systematic review and Bayesian network meta-analysis. J Eur Acad Dermatol Venereol. 2024;38(5):835\u201343.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10244","key":"1583_CR28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","volume":"396","author":"D Rosmarin","year":"2020","unstructured":"Rosmarin D, Pandya AG, Lebwohl M, Grimes P, Hamzavi I, Gottlieb AB, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020;396(10244):110\u201320.","journal-title":"Lancet"},{"key":"1583_CR29","doi-asserted-by":"publisher","first-page":"1341632","DOI":"10.3389\/fimmu.2024.1341632","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Jiang G. Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses. Front Immunol. 2024;15:1341632.","journal-title":"Front Immunol"},{"issue":"3","key":"1583_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/bjd\/ljad079","volume":"190","author":"J Vyas","year":"2024","unstructured":"Vyas J, Johns JR, Ali FM, Singh RK, Ingram JR, Salek S, et al. A systematic review of 454 randomized controlled trials using the Dermatology life quality index: experience in 69 diseases and 43 countries. Br J Dermatol. 2024;190(3):315\u201339.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1583_CR31","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/bjd\/ljae228","volume":"191","author":"JR Johns","year":"2024","unstructured":"Johns JR, Vyas J, Ali FM, Ingram JR, Salek S, Finlay AY. The Dermatology Life Quality Index as the primary outcome in randomized clinical trials: a systematic review. Br J Dermatol. 2024;191(4):497\u2013507.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1583_CR32","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"1583_CR33","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/exd.14753","volume":"32","author":"S Sadeghi","year":"2023","unstructured":"Sadeghi S, Mohandesi NA. Efficacy and safety of topical JAK inhibitors in the treatment of atopic dermatitis in paediatrics and adults: a systematic review. Exp Dermatol. 2023;32(5):599\u2013610.","journal-title":"Exp Dermatol"},{"issue":"3","key":"1583_CR34","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","volume":"13","author":"C Samuel","year":"2023","unstructured":"Samuel C, Cornman H, Kambala A, Kwatra SG. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther. 2023;13(3):729\u201349.","journal-title":"Dermatol Ther"},{"issue":"11","key":"1583_CR35","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1007\/s12325-022-02281-4","volume":"39","author":"T Bieber","year":"2022","unstructured":"Bieber T, Feist E, Irvine AD, Harigai M, Haladyj E, Ball S, et al. A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19. Adv Ther. 2022;39(11):4910\u201360.","journal-title":"Adv Ther"},{"issue":"12","key":"1583_CR36","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.36849\/JDD.7187","volume":"21","author":"S Daniele","year":"2022","unstructured":"Daniele S, Bunick C. JAK inhibitor safety compared to traditional systemic immunosuppressive therapies. J Drugs Dermatol. 2022;21(12):1298\u2013303.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"1583_CR37","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ard.2025.01.024","volume":"84","author":"V Konzett","year":"2025","unstructured":"Konzett V, Smolen JS, Nash P, Winthrop K, Aletaha D, Dorner T, et al. Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases\u2014a systematic literature review informing the 2024 update of an international expert consensus statement. Ann Rheum Dis. 2025;84(5):697\u2013715.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1583_CR38","first-page":"4","volume":"27","author":"MMK Shalabi","year":"2022","unstructured":"Shalabi MMK, Garcia B, Coleman K, Siller A Jr, Miller AC, Tyring SK. Janus kinase and tyrosine kinase inhibitors in dermatology: a review of their utilization, safety profile and future applications. Skin Ther Lett. 2022;27(1):4\u20139.","journal-title":"Skin Ther Lett."},{"issue":"7","key":"1583_CR39","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3390\/jpm14070775","volume":"14","author":"L Calabrese","year":"2024","unstructured":"Calabrese L, D\u2019Onghia M, Lazzeri L, Rubegni G, Cinotti E. Blocking the IL-4\/IL-13 axis versus the JAK\/STAT Pathway in atopic dermatitis: how can we choose? J Pers Med. 2024;14(7):775.","journal-title":"J Pers Med."},{"key":"1583_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13030384","author":"M Tampa","year":"2023","unstructured":"Tampa M, Mitran CI, Mitran MI, Georgescu SR. A new horizon for atopic dermatitis treatments: JAK inhibitors. J Pers Med. 2023. https:\/\/doi.org\/10.3390\/jpm13030384.","journal-title":"J Pers Med"},{"issue":"12","key":"1583_CR41","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00228-022-03400-4","volume":"78","author":"C Alves","year":"2022","unstructured":"Alves C, Penedones A, Mendes D, Batel MF. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis. Eur J Clin Pharmacol. 2022;78(12):1923\u201333.","journal-title":"Eur J Clin Pharmacol"},{"key":"1583_CR42","doi-asserted-by":"publisher","first-page":"1382728","DOI":"10.3389\/fimmu.2024.1382728","volume":"15","author":"C Ma","year":"2024","unstructured":"Ma C, Liu M, Cheng Y, Wang X, Zhao Y, Wang K, et al. Therapeutic efficacy and safety of JAK inhibitors in treating polymyositis\/dermatomyositis: a single-arm systemic meta-analysis. Front Immunol. 2024;15:1382728.","journal-title":"Front Immunol"},{"issue":"1","key":"1583_CR43","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/jvc2.551","volume":"4","author":"AJ Teixeira","year":"2025","unstructured":"Teixeira AJ, Duong JQ, Parraga SP, Feldman SR. Presenting JAK inhibitor safety information to dermatology patients. JEADV Clin Pract. 2025;4(1):12\u201320.","journal-title":"JEADV Clin Pract."},{"issue":"12","key":"1583_CR44","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1111\/1346-8138.16126","volume":"48","author":"L Zhang","year":"2021","unstructured":"Zhang L, Du D, Wang L, Guo L, Jiang X. Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: a network meta-analysis. J Dermatol. 2021;48(12):1877\u201383.","journal-title":"J Dermatol"},{"issue":"9","key":"1583_CR45","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047\u201355.","journal-title":"JAMA Dermatol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01583-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01583-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01583-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:32:47Z","timestamp":1787059967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01583-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1583"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01583-7","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is a systematic review and meta-analysis of previously published data and did not involve human participants or animal subjects.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The R code used for statistical analyses is available from the corresponding author upon reasonable request.","order":5,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data generated or analyzed during this study are included in this article. Further inquiries can be directed to the corresponding author.","order":6,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N.F.Z.: Conceptualization, literature search, data extraction, writing\u2014original draft preparation. K.S.: Literature search, data extraction, risk of bias assessment, statistical analysis, writing\u2014review & editing. A.K.: Study selection, data extraction, writing\u2014review & editing, supervision. R.Y.Y.: Data extraction, risk of bias assessment, visualization. S.A.B.: Validation, writing\u2014review & editing. N.F.Z., K.S., and A.K. contributed equally to this manuscript. All authors have read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}